- Generic name
- Piperacillin + Tazobactam
- Strength
- 2 gm + 250 mg/vial
- Dosage form
- Injection
- Manufactured by
- Synovia Pharma PLC.
Brodactam 2.25 g Injection
About Brodactam 2.25 g 2 gm + 250 mg/vial Injection
Brodactam 2.25 g is an injection that combines piperacillin, a penicillin-type antibiotic, with tazobactam, which helps protect it from bacterial enzymes. It belongs to the beta-lactam antibiotic group and is given by a healthcare professional for certain moderate to severe infections.
There are 8 brands of Piperacillin + Tazobactam listed in Bangladesh. The lowest listed price is Brodactam (2 gm+0.25 gm)/vial IV Infusion at ৳ 602.00 per unit.
What is Brodactam 2.25 g 2 gm + 250 mg/vial Injection?
Brodactam 2.25 g is a vial of powder for injection made by Synovia Pharma PLC. It contains piperacillin 2 gm and tazobactam 250 mg. Piperacillin is a broad-spectrum penicillin that kills bacteria by interfering with their cell wall. Tazobactam blocks enzymes that some bacteria use to resist penicillins, which widens the range of bacteria piperacillin can act against. The injection is given into a vein by a doctor or nurse, usually in a hospital or clinic. It is used for certain moderate to severe infections caused by bacteria that are susceptible to the combination. Your doctor decides whether it suits your infection.
Uses of Brodactam 2.25 g
Brodactam 2.25 g is used to treat moderate to severe bacterial infections caused by organisms that are susceptible to piperacillin and tazobactam. These include certain intra-abdominal infections. Because it is an injection given in a healthcare setting, it is generally reserved for people who need treatment under medical supervision. Not every infection responds to this antibiotic, so the doctor assesses the type and severity of the infection before choosing it. Ask the doctor if you are unsure why it has been prescribed for you.
How to use Brodactam 2.25 g
Brodactam 2.25 g comes as a powder in a vial that a healthcare professional prepares and gives as an intravenous infusion. You will not prepare or inject it yourself. A doctor or nurse sets the dose, how often it is given and how long the course lasts, based on your infection and your health. Tell the staff about any allergies or other medicines before it is given. Follow the instructions you are given for your treatment and check with the doctor about anything unclear.
Side effects of Brodactam 2.25 g
Common side effects involve the skin, such as rash, itching and purpura, and the stomach and bowel, including diarrhoea, constipation, nausea, vomiting, indigestion and abdominal pain. Some people have fever, chills or a reaction at the injection site. Less common effects include allergic reactions, which can be serious, fungal infections, inflammation of the bowel, low blood sugar, muscle and joint pain and trouble sleeping. Tell the doctor or nurse promptly about any new or worsening symptom during treatment.
Safety and precautions
Do not receive Brodactam 2.25 g if you have had an allergic reaction to penicillins, cephalosporins or beta-lactamase inhibitors. Serious allergic reactions and severe skin reactions have occurred, so treatment is stopped if a reaction develops; tell staff at once about rash, swelling or breathing trouble. Blood counts may need checking during long treatment. Piperacillin and tazobactam cross the placenta, and there is not enough information to judge the risk in pregnancy; piperacillin passes into breast milk. Tell the doctor if you are pregnant, breastfeeding or have kidney problems, and ask the doctor first about any concern.
Frequently asked questions
What kind of medicine is Brodactam 2.25 g and what is it used for?
It is a beta-lactam antibiotic injection combining piperacillin and tazobactam. It is used for certain moderate to severe bacterial infections, including some intra-abdominal infections, caused by bacteria that are susceptible to the combination. The doctor decides whether it is appropriate for your infection.
Which medicines may interact with Brodactam 2.25 g?
Aminoglycoside antibiotics such as tobramycin may interact with piperacillin, and their levels may need monitoring in some patients, particularly those with kidney problems on dialysis. Because other interactions are possible, give the doctor a full list of medicines you take before treatment starts.
Who should avoid Brodactam 2.25 g or ask the doctor first?
People with a history of allergic reactions to penicillins, cephalosporins or beta-lactamase inhibitors should not receive it. Tell the doctor before treatment if you are pregnant or breastfeeding, have kidney problems, or have had an allergic reaction to any antibiotic, so the doctor can decide what is suitable.
How is Brodactam 2.25 g given and who decides the dose?
It is prepared from a vial and given as an intravenous infusion by a doctor or nurse in a healthcare setting. The doctor decides the dose, how often it is given and the length of the course. Do not attempt to prepare or inject it yourself, and ask the doctor about anything you do not understand.
Indications
Intra-abdominal Infections: Appendicitis (complicated by rupture or abscess) and peritonitis caused by β-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus.
Skin and Skin Structure Infections: Uncomplicated and complicated skin and skin structure infections, including Cellulites, cutaneous abscesses and ischemic/diabetic foot infections caused by β-lactamase producing isolates of Staphylococcus aureus.
Female Pelvic Infections: Postpartum endometritis or pelvic inflammatory disease caused by β-lactamase producing isolates of Escherichia coli.
Community-acquired pneumonia: Community-acquired pneumonia (moderate severity only) caused by β lactamase producing isolates of Haemophilus influenzae.
Nosocomial pneumonia: Nosocomial pneumonia (moderate to severe) caused by β-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumanii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside).
Pharmacology
Dosage & Administration
Adult Patients: The usual total daily dose of Piperacillin and tazobactam for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). The usual duration of treatment is from 7 to 10 days.
Nosocomial Pneumonia: Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). The recommended duration of the treatment for nosocomial pneumonia is 7 to 14 days. Treatment with the aminoglycoside should be continued in patients from whom Pseudomonas aeroginosa is isolated.
Pediatric Patients: For children with appendicitis and/or peritonitis 9 months of age or older, weighing up to 40 kg, and with normal renal function, the recommended piperacillin and tazobactam dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours. For pediatric patients between 2 months and 9 months of age, the recommended dosage based on Pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours. Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose. It has not been determined how to adjust piperacillin and tazobactam dosage in pediatric patients with renal impairment.
Interaction
Sequential administration of pipercillin and tazobactam and tobramycin to patients with either normal renal function or mild to moderate renal impairment has been shown to modestly decrease serum concentrations of tobramycin but no dosage adjustment is considered necessary.
Probenecid: Probenecid administered concomitantly with piperacillin and tazobactam prolongs the half-life of piperacillin by 21% and that of tazobactam by 71% because probenecid inhibits tubular renal secretion of both piperacillin and tazobactam. Probenecid should not be co-administered with Pipercillin and tazobactam unless the benefit outweighs the risk.
Anticoagulants: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.
Vecuronium: Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vacuronium, piperacillin and tazobactam could produce the same phenomenon if given along with vecuronium. Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
Methotrexate: Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion. The impact of tazobactam on the elimination of methotrexate has not been evaluated. If concurrent therapy is necessary, serum concentrations of methotrexate as well as the signs and symptoms of methotrexate toxicity should be frequently monitored.
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Piperacillin and tazobactam may cause severe cutaneous adverse reactions, such as Stevens- Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. Discontinue Piperacillin and tazobactam for progressive rashes.
Hematological effects (including bleeding, leukopenia and neutropenia) have occurred. Monitor hematologic tests during prolonged therapy.
Nephrotoxicity in critically ill patients has been observed; the use of Piperacillin and tazobactam was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients. Based on this study, alternative treatment options should be considered in the critically ill population. If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with Piperacillin and tazobactam.
Clostridium difficile associated diarrhea: Evaluate patients if diarrhea occurs.
Overdose Effects
Storage Conditions
Alternative brands of Piperacillin + Tazobactam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.